Article Text

Download PDFPDF

CPC-148 Treatment of Severe Psoriasis with Biologicals
  1. J Ruiz Gutiérrez1,
  2. G Roustán Gullón2,
  3. P Calabuig Martínez1,
  4. A Torralba Arranz1
  1. 1Hospital Universitario Puerta de Hierro Majadahonda, Pharmacy, Majadahonda (Madrid), Spain
  2. 2Hospital Universitario Puerta de Hierro Majadahonda, Dermatology, Majadahonda (Madrid), Spain


Background Biological drugs are a relatively new class of treatment for severe psoriasis (SP).

Purpose To analyse the use and outcomes of biologicals in SP.

Materials and Methods Retrospective observational study for 23 months of patients with SP who had not previously received biological therapy (treatment-naive). Data were collected from the pharmacy outpatient dispensing programme and the clinical history.

Results 46 treatment-naive patients started treatment, mean age 43 (17–83), 58.7% men. They were treated with: adalimumab (20 patients), infliximab (17) and ustekinumab (9); none with etanercept.

Abstract CPC-148 Table 1

The causes of the discontinuation/change of treatment were:

Abstract CPC-148 Table 2

Adverse reactions that caused withdrawal or change were:

Abstract CPC-148 Table 3

Conclusions The first biological in treatment-naive patients was 1st) adalimumab, 2nd) infliximab and 3rd) ustekinumab. Ustekinumab was the biological drug that achieved the best retention rate. Several patients discontinued their treatment with adalimumab because of good response, since it can be used in intermittent treatment schemes. Change in treatment was more frequent with infliximab, mainly because of infusion reactions. Ustekinumab was the only biological that didn’t cause adverse reactions that caused withdrawal or change.

No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.